top of page
Single_Cell_Gradient_9a.png

Biocentury Emerging Company Profile  -  Accession: precisely targeted oncolytic viruses

Bent Jakobsen’s newest biotech is replacing the virus’ natural tropisms with an integrin-based cancer targeting mechanism - read the article by Richard Guy, Biopharma Analyst, here >



bc-accession-precisely-targeted-oncolytic-viruses
.pdf
Download PDF • 234KB



Comments


bottom of page